News >

Cabozantinib Improves Survival in Phase III HCC Trial

Jason Harris
Published: Monday, Oct 16, 2017

Gisela Schwab, MD

Gisela Schwab, MD
Cabozantinib (Cabometyx) improved overall survival (OS) versus placebo in patients with advanced hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar), meeting the primary endpoint of the phase III CELESTIAL trial.

The most common grade 3/4 adverse events were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Nearly 2 in 3 patients (59%) required dose reductions.
Kelley RK, Verslype C, Cohn AL, et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017;28(3):528-534. doi: 10.1093/annonc/mdw651.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x